SVCM
ARQT icon

Saturn V Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Saturn V Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-178,217
Closed -$1.96M – 21
2023
Q1 		$1.96M Sell
178,217
-308,962
-63% -$4.47M 1.46% 15
2022
Q4 		$8.79M Buy
+487,179
New +$8.51M 7.29% 4

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Saturn V Capital Management's ARQT Position: Q2 2023 in Review

Saturn V Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 178,217 shares — an estimated $1.96M sold.

Saturn V Capital Management first reported a position in ARQT in Q4 2022 and held it in 2 quarters. The position peaked at $8.79M in Q4 2022. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • Saturn V Capital Management reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Saturn V Capital Management sold 178,217 Arcutis Biotherapeutics shares in Q2 2023, an estimated $1.96M.
  • Saturn V Capital Management first reported a position in Arcutis Biotherapeutics in Q4 2022 and held it in 2 quarters.
  • Saturn V Capital Management's Arcutis Biotherapeutics position peaked at $8.79M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Saturn V Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.